ArticleJournal of hepatocellular carcinoma2025
Beta-Catenin Mutations Can Impact on the Interplay Between Tumor and Immune Cells and Hepatic Microbiota in Hepatocellular Cancer.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Emerging evidence links alterations in the tumor microbiome to therapeutic responses to immunotherapy. Alterations in β-catenin are among the most frequently observed oncogenic drivers of hepatocarcinogenesis and are associated with T-cell exclusion. However, their effect on the immune cell environment and microbiome in hepatocellular cancer is not well understood. We hypothesized that β-catenin could modulate the immune microenvironment through alterations in the secretome and release of extracellular vesicles (EV) that mediate tumor and immune cell interactions and increase tumor growth within regions with attenuated immune activity and reduced microbial diversity. Methods: We used a synthetic transgenic murine model of β-catenin-driven hepatocarcinogenesis to analyze microbiome composition, diversity, and immune cell profiles in vivo. Tumor and stool samples were collected from mice with early- or late-stage hepatocellular carcinoma and were used for profiling. Results: The microbiome associated with intrahepatic tumors differs from that in non-tumoral regions, normal liver tissues, and gut tissues. Constitutive β-catenin expression modulates lipopolysaccharide-mediated signaling in macrophages and alters the secretion of immunomodulatory chemokines and cytokines. Tumoral immune cell profiles differed from those in hepatic tissues. EV-mediated signaling between immune cells and epithelial cells with mutant β-catenin and immune cells modulates immune cell populations in vitro and in vivo. Conclusion: Mutations in β-catenin can drive immune responses through EV-based tumor cell-immune cell interactions to modulate both the tumor microflora and immune microenvironment. A potential strategy to augment responses to immunotherapy for hepatocellular cancer could target these interactions to restore microbial diversity or immune cell infiltration within the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.